20 June 2023
SHARE NOW
ATW
Cell Therapy
Gene Therapy
Scaling Up
Strategy
Viral/Non-Viral Vectors
This Briefing from Advanced Therapies Week 2023 focusses on scaling up, scaling out and going beyond scale with AAV manufacturing.
During this session, Andrew Moreo, Head of Process Development at Andelyn Biosciences discusses key considerations for scaling up (linear) and scaling out (reproducibility), among other key areas beyond scaling where performance and flexibility become priorities, in the context of a platform for AAV manufacturing.
This Briefing was presented at Advanced Therapies Week 2023, in partnership with Andelyn Biosciences.
More like this
Taysha Gene Therapies Halts its TSHA-120 Program for Giant Axonal Neuropathy Treatment
Taysha is discontinuing the development of TSHA-120 in GAN following the Type C meeting feedback from the FDA
21 September 2023
Oxford Biomedica Explores Acquisition of ABL Europe in Collaboration with Institut Mérieux
Oxford Biomedica in Exclusive Talks to Acquire ABL Europe from Institut Mérieux.
20 September 2023
The Cell & Gene Therapy Manufacturing Capacity Map
The only live, interactive manufacturing capacity compendium for the advanced therapies industry.
20 September 2023
